Skip to main content
OpenTrials
Completed

NCT Number: NCT02330926

Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.

There is an urgency for improving management, but there is no consensus on the optimal treatment for cancer cachexia. Several single therapies for cancer cachexia have been examined in clinical trials, with disappointing overall results. As multiple factors are responsible for the development of cachexia, it has been argued that optimal cachexia interventions should target all components: multimodal therapy for a multimodal problem.

The overall aim of this study is to early prevent the development of cachexia rather than treatment late in the disease trajectory. From a patient perspective a short term effect will be to improve physical and psychological function, to reduce symptom burden and to improve survival. In other words live a longer and better life during and after chemotherapy. Direct effects of the cachexia intervention are expected to be reduction of weight and muscle loss, and improved physical activity and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cachexia Body Weight Body Weight Changes Neoplasms Pathological Conditions, Signs and Symptoms Signs and Symptoms Thinness Weight Loss

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CA4 Brampton Civic Hospital, Brampton, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma where the diagnosis is based on histological, radiological or multidisciplinary team (MDT) evaluation
  • non-small cell lung cancer (stage III or IV), pancreatic adenocarcinoma (stage III or IV), due to commence first or second line anticancer treatment (defined as chemotherapy, chemo-radiotherapy, targeted therapy or immunotherapy)
  • staging CT within 4 weeks of commencement of anti-cancer therapy (in patients where staging CT is out-with this period, further CT scanning will be undertaken. PETCT's are also appropriate)
  • completed all other baseline assessments within one week prior to first course of anti-cancer treatment
  • written informed consent
  • able to comply with trial interventions (in the opinion of referring clinician) e.g. willing and able to do light exercise and take oral nutritional supplements as well as no major contraindications against ibuprofen.
  • Karnofsky Performance Status >70

Exclusion criteria

  • Neuro-endocrine pancreatic cancer
  • Creatinine clearance <30ml/min
  • Receiving parenteral nutrition or enteral nutrition via feeding tube
  • receiving neo-adjuvant anti-cancer therapy
  • BMI >30 kg/m2
  • Use of appetite stimulants or anabolic/anti-catabolic agents (such as megestrol acetate, progestational agents, marijuana growth hormone, dronabinol, or other anabolic agent) within 30 days prior to study baseline
  • Concomitant steroid (>10mg/d prednisolone or equivalent) treatment for less than three months prior to inclusion (inhaled, optical or pulsed oral steroids (up to 10 days use) are permitted)
  • Concomitant long term (>1 week) nonsteroidal anti-inflammatory drugs (NSAID) or aspirin treatment
  • pregnancy, breast-feeding or of child bearing potential (that is not postmenopausal or permanently sterilised) age and not using adequate contraception (oral, injected, implanted or hormonal methods of contraception, intrauterine device and barrier method)
  • Concomitant anti-coagulant treatment (e.g. warfarin or heparin)

Treatment and study plan

Standard care

Other

Routine oncology and palliative care

nutritional supplements and advice

Dietary Supplement

n-3 PUFA enriched supplements, dietary advice

home-based self-assisted exercise program

Behavioral

Strength and aerobic

Ibuprofen

Drug

400mgx3

Primary outcomes

  1. change in body weight

    Time frame: 6 weeks

    body weight (Kg)

Secondary outcomes

  1. change in muscle mass

    Time frame: 6 weeks

    CT L3 cross sectional area

  2. change in physical activity

    Time frame: 6 weeks

    ActivPAL step count

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Collaborators

  • Cancer Research UK Edinburgh Centre
  • Cantonal Hospital of St. Gallen
  • Cedars-Sinai Medical Center
  • Chelsea and Westminster NHS Foundation Trust
  • Cross Cancer Institute
  • Guy's and St Thomas' NHS Foundation Trust
  • Jewish General Hospital
  • Malteser Krankenhaus Seliger Gerhardt
  • NHS Forth Valley
  • Oslo University Hospital
  • Ottawa Regional Cancer Centre
  • Queen Margaret Hospital, Dunfermline
  • St. Olavs Hospital
  • The Beatson West of Scotland Cancer Centre
  • Tumor Biology Center Freiburg
  • Tumor Zentrum Aarau

Registry information

Official study title

A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

Acronym: MENAC

Important dates

Study start
2015
Primary completion
2023
Study completion
2023
First posted
Jan 5, 2015
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.